Trial Profile
Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: a Randomized, Multicenter, Phase 3 Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Sintilimab (Primary) ; Cisplatin; Gemcitabine; Ropidoxuridine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CONTINUUM
- 06 Jun 2023 Primary endpoint (Failure-free survival (FFS)) has been met according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results assessing safety and efficacy of sintilimab plus induction chemotherapy and concurrent chemoradiotherapy in locoregionally-advanced nasopharyngeal carcinoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 16 May 2023 According to an Innovent Biologics media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.